Subcutaneous Implantable Defibrillator (S-ICD)

MARKETVUE® REPORT: Surgery remains the only option for the ~50% of LQTS patients refractory or intolerant to beta blockers

Retrieved on: 
Mardi, novembre 7, 2023
Long QT syndrome, Libido, ICD, Physician, Video-assisted thoracoscopic surgery, REACH, Risk, Perforation, LQTS, Depression, Subcutaneous Implantable Defibrillator (S-ICD), LCSD, Patient, Fatigue, Pharmaceutical industry

NEWTON, Mass., Nov. 7, 2023 /PRNewswire/ -- Long QT syndrome (LQTS) is a rare congenital cardiac arrhythmia characterized by a prolonged recovery in cardiac action potential that can cause deadly arrhythmias.

Key Points: 
  • According to LQTS experts interviewed by REACH , most cases of LQTS, especially LQTS type 1, are well-controlled by the current standard of care—beta blockers—despite less the less-than-ideal side effects they cause (e.g., fatigue, depression, decreased libido).
  • However, for high-risk patients that experience breakthrough events despite maximal tolerated beta blocker treatment, physicians turn to surgical options that include implantable cardioverter-defibrillators (ICDs) or left cardiac sympathetic denervation (LCSD).
  • Additionally, while a large majority of patients are well-managed by beta blockers, up to half of these patients struggle with the side effects and could benefit from a better-tolerated treatment option.
  • A lot of those are my patients with long QT syndrome who have had an ICD since childhood."

MARKETVUE® REPORT: Arrhythmogenic Cardiomyopathy Gene Therapy Research Gains Momentum

Retrieved on: 
Mardi, novembre 7, 2023
Catheter ablation, ICD, PKP2, Penetrance, Physician, Arrhythmogenic cardiomyopathy, REACH, Quality of life, Disease, Risk, Arrhythmia, Subcutaneous Implantable Defibrillator (S-ICD), ACM, Patient, Heart, Mutation, Medical device, Vaccine

NEWTON, Mass., Nov. 7, 2023 /PRNewswire/ -- Arrhythmogenic Cardiomyopathy (ACM) is a rare hereditary cardiac disorder characterized by progressive replacement of myocardial tissue with fibrofatty deposits, leading to life-threatening arrhythmias and cardiac dysfunction.

Key Points: 
  • ~70% of physicians surveyed by REACH Market Research report there is an extremely high unmet medical need for novel treatments for ACM.
  • NEWTON, Mass., Nov. 7, 2023 /PRNewswire/ -- Arrhythmogenic Cardiomyopathy (ACM) is a rare hereditary cardiac disorder characterized by progressive replacement of myocardial tissue with fibrofatty deposits, leading to life-threatening arrhythmias and cardiac dysfunction.
  • ACM patients typically receive treatment with beta blockers and anti-arrhythmic drugs to manage symptoms and arrhythmias.
  • To access REACH's MarketVue® Report on ACM, visit https://reachmr.com or contact us at [email protected] .

LATE-BREAKING TRIAL PRESENTED AT HRS SHOWS MEASURABLE DIFFERENCE IN OUTCOMES BETWEEN PATIENTS BY SEX

Retrieved on: 
Vendredi, juin 9, 2023
Arrhythmia, Heart Rhythm Society, Male, NICM, University, Subcutaneous Implantable Defibrillator (S-ICD), Life, CRT-D, Woman, Research, Tachycardia, Doctor of Philosophy, Physician, Cardiomyopathy, Death, Cardiac resynchronization therapy, Conference, Female, Birth control, Medical device, Nursing, MD, Patient

LAKE OSWEGO, Ore., June 9, 2023 /PRNewswire/ -- Data presented at Heart Rhythm Society's 2023 Conference show a measurable difference in outcomes between male and female patients when looking at one-year ventricular tachyarrhythmia or death rates in patients with non-ischemic cardiomyopathy (NICM) with an ICD or CRT-D.

Key Points: 
  • Historically, women have been underrepresented in studies of patients with implantable cardiovascular medical devices, making it impossible to draw measurable conclusions of differences between sex.
  • "The BIO-LIBRA model will lead the way women are enrolled in medical device studies in the next decades," says Dr. Valentina Kutyifa.
  • "A large, properly powered study was much needed to better understand sex-specific outcomes in non-ischemic cardiomyopathy patients, and the BIO-LIBRA study sheds new light on the intricate interconnected relationship between sex and race on outcomes."
  • Contemporary Outcomes of Non-Ischemic Cardiomyopathy Patients with an Implanted Defibrillator or Cardiac Resynchronization Therapy (BIO-LIBRA).

Feinstein Institutes, Northwell electrophysiologist successfully implant first modular cardiac rhythm management system in novel clinical trial

Retrieved on: 
Vendredi, octobre 21, 2022
Health, Medical Devices, Surgery, Health Technology, Clinical Trials, Cardiology, Biotechnology, Physician, LinkedIn, Communication, Risk, Medicine, CRM, Population, Science, Arrest, Medical research, MPS, Patient, Research, Multimedia, Feinstein Institute for Medical Research, Mental health, Electrophysiology, EMPOWER, Cancer, Emergency department, Molecular medicine, Subcutaneous Implantable Defibrillator (S-ICD), Laurence, Autoimmunity, Genetics, Clinical trial, Shock, Nursing, Cardiac arrest, Northwell Health, ATP, North Shore University Hospital, Heart, Death, Perspiration, Credit, Coma, Medical device, Boston Scientific, MD

Like a paramedic in your chest, a team of Northwell Health clinicians, electrophysiologists and clinical trial investigators at The Feinstein Institutes for Medical Research successfully implanted a modular cardiac rhythm management (CRM) system in the first patient to be enrolled in the Boston Scientific MODULAR ATP clinical trial.

Key Points: 
  • Like a paramedic in your chest, a team of Northwell Health clinicians, electrophysiologists and clinical trial investigators at The Feinstein Institutes for Medical Research successfully implanted a modular cardiac rhythm management (CRM) system in the first patient to be enrolled in the Boston Scientific MODULAR ATP clinical trial.
  • View the full release here: https://www.businesswire.com/news/home/20221021005348/en/
    Laurence M. Epstein, MD (center right) implanted the first patient in Boston Scientifics MODULAR ATP clinical trial at North Shore University Hospital.
  • The trial will also investigate the system and procedure-related complication-free rate of the EMPOWER MPS.
  • The MODULAR ATP trial will enroll up to 60 centers in the U.S., Canada and Europe up to 300 patients.